APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmacogenomics Technology (Theranostics & CDx)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pharmacogenomics Technology (Theranostics & CDx) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchPharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacogenomics Technology (Theranostics & CDx) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pharmacogenomics Technology (Theranostics & CDx) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Global Pharmacogenomics Technology (Theranostics & CDx) key players include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific etc. Global top three players hold a share over 65%. North America is the largest market, with a share about 40%, followed by Europe and China, both have a share about 40 percent.

Report Includes

This report provides an overview of the global Pharmacogenomics Technology (Theranostics & CDx) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Pharmacogenomics Technology (Theranostics & CDx) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmacogenomics Technology (Theranostics & CDx) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Pharmacogenomics Technology (Theranostics & CDx) market size, projected growth trends, production technologies, key applications, and end-use industries.

Pharmacogenomics Technology (Theranostics & CDx) Segment by Company

Illumina

F. Hoffmann-La Roche

Agilent

Abbott

Thermo Fisher Scientific

Qiagen

Guardant Health

MGI Tech

Amoy Diagnostics

BGI Group

Pharmacogenomics Technology (Theranostics & CDx) Segment by Type

Instruments

Reagents and Consumables

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Application

Tumour

Diabetes

Mental Illness

Cardiovascular Disease

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Pharmacogenomics Technology (Theranostics & CDx) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmacogenomics Technology (Theranostics & CDx) industry.

Chapter 3: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacogenomics Technology (Theranostics & CDx)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Instruments Table 3. Key Players of Reagents and Consumables Table 4. Key Players of Other Table 4. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Tumour Table 6. Key Players of Diabetes Table 7. Key Players of Mental Illness Table 8. Key Players of Cardiovascular Disease Table 9. Key Players of Other Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2021-2026) Table 13. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2027-2032) Table 15. Pharmacogenomics Technology (Theranostics & CDx) Industry Trends Table 16. Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers Table 17. Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges Table 18. Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints Table 19. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Company (2021-2026) Table 21. Global Pharmacogenomics Technology (Theranostics & CDx) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Pharmacogenomics Technology (Theranostics & CDx) Key Company Head Office and Area Served Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Company, Product Type & Application Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2021-2026) Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2027-2032) Table 32. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021-2026) Table 36. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2027-2032) Table 37. Illumina Company Information Table 38. Illumina Business Overview Table 39. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 41. Illumina Recent Development Table 42. F. Hoffmann-La Roche Company Information Table 43. F. Hoffmann-La Roche Business Overview Table 44. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 46. F. Hoffmann-La Roche Recent Development Table 47. Agilent Company Information Table 48. Agilent Business Overview Table 49. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 51. Agilent Recent Development Table 52. Abbott Company Information Table 53. Abbott Business Overview Table 54. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 56. Abbott Recent Development Table 57. Thermo Fisher Scientific Company Information Table 58. Thermo Fisher Scientific Business Overview Table 59. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 61. Thermo Fisher Scientific Recent Development Table 62. Qiagen Company Information Table 63. Qiagen Business Overview Table 64. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 66. Qiagen Recent Development Table 67. Guardant Health Company Information Table 68. Guardant Health Business Overview Table 69. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 71. Guardant Health Recent Development Table 72. MGI Tech Company Information Table 73. MGI Tech Business Overview Table 74. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 76. MGI Tech Recent Development Table 77. Amoy Diagnostics Company Information Table 78. Amoy Diagnostics Business Overview Table 79. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 81. Amoy Diagnostics Recent Development Table 82. BGI Group Company Information Table 83. BGI Group Business Overview Table 84. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 86. BGI Group Recent Development Table 87. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 88. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032) & (US$ Million) Table 89. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 90. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032) & (US$ Million) Table 91. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) Table 93. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032) Table 94. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 95. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032) & (US$ Million) Table 96. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 97. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032) & (US$ Million) Table 98. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) Table 100. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032) Table 101. China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 102. China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032) & (US$ Million) Table 103. China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 104. China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032) & (US$ Million) Table 105. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 106. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032) & (US$ Million) Table 107. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 108. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032) & (US$ Million) Table 109. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) Table 111. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032) Table 112. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026) & (US$ Million) Table 113. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032) & (US$ Million) Table 114. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026) & (US$ Million) Table 115. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032) & (US$ Million) Table 116. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026) Table 118. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Product Image Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type: 2025 VS 2032 Figure 4. Instruments Image Figure 5. Reagents and Consumables Image Figure 6. Other Image Figure 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application: 2025 VS 2032 Figure 9. Tumour Image Figure 10. Diabetes Image Figure 11. Mental Illness Image Figure 12. Cardiovascular Disease Image Figure 13. Other Image Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2021-2032) Figure 23. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021-2032) Figure 25. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 26. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032) Figure 27. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032) Figure 28. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 29. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 30. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 32. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032) Figure 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032) Figure 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 36. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 37. France Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 39. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 40. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 42. China Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 43. China Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032) Figure 44. China Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032) Figure 45. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 46. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032) Figure 47. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032) Figure 48. Asia Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 49. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 53. India Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 54. Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032) Figure 59. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 64. UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 66. Chile Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Reagents and Consumables
  • Other
Applications
  • Tumour
  • Diabetes
  • Mental Illness
  • Cardiovascular Disease
  • Other
Companies covered
  • Illumina
  • F. Hoffmann-La Roche
  • Agilent
  • Abbott
  • Thermo Fisher Scientific
  • Qiagen
  • Guardant Health
  • MGI Tech
  • Amoy Diagnostics
  • BGI Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Instruments
  5. 1.2.3 Reagents and Consumables
  6. 1.2.4 Other
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Tumour
  10. 1.3.3 Diabetes
  11. 1.3.4 Mental Illness
  12. 1.3.5 Cardiovascular Disease
  13. 1.3.6 Other
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
  16. 1.5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2026)
  18. 1.5.3 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
  1. 2.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
  2. 2.2 Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers
  3. 2.3 Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges
  4. 2.4 Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Company (2021-2026)
  2. 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Pharmacogenomics Technology (Theranostics & CDx) Key Company Head office and Area Served
  4. 3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Company, Product Type & Application
  5. 3.5 Global Pharmacogenomics Technology (Theranostics & CDx) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Pharmacogenomics Technology (Theranostics & CDx) Tier 1, Tier 2, and Tier 3
4 Pharmacogenomics Technology (Theranostics & CDx) Market by Type
  1. 4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2032)
  3. 4.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Type (2021-2032)
5 Pharmacogenomics Technology (Theranostics & CDx) Market by Application
  1. 5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2032)
  3. 5.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Illumina
  2. 6.1.1 Illumina Company Information
  3. 6.1.2 Illumina Business Overview
  4. 6.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  6. 6.1.5 Illumina Recent Developments
  7. 6.2 F. Hoffmann-La Roche
  8. 6.2.1 F. Hoffmann-La Roche Company Information
  9. 6.2.2 F. Hoffmann-La Roche Business Overview
  10. 6.2.3 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  12. 6.2.5 F. Hoffmann-La Roche Recent Developments
  13. 6.3 Agilent
  14. 6.3.1 Agilent Company Information
  15. 6.3.2 Agilent Business Overview
  16. 6.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  18. 6.3.5 Agilent Recent Developments
  19. 6.4 Abbott
  20. 6.4.1 Abbott Company Information
  21. 6.4.2 Abbott Business Overview
  22. 6.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  24. 6.4.5 Abbott Recent Developments
  25. 6.5 Thermo Fisher Scientific
  26. 6.5.1 Thermo Fisher Scientific Company Information
  27. 6.5.2 Thermo Fisher Scientific Business Overview
  28. 6.5.3 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  30. 6.5.5 Thermo Fisher Scientific Recent Developments
  31. 6.6 Qiagen
  32. 6.6.1 Qiagen Company Information
  33. 6.6.2 Qiagen Business Overview
  34. 6.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  36. 6.6.5 Qiagen Recent Developments
  37. 6.7 Guardant Health
  38. 6.7.1 Guardant Health Company Information
  39. 6.7.2 Guardant Health Business Overview
  40. 6.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  42. 6.7.5 Guardant Health Recent Developments
  43. 6.8 MGI Tech
  44. 6.8.1 MGI Tech Company Information
  45. 6.8.2 MGI Tech Business Overview
  46. 6.8.3 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  48. 6.8.5 MGI Tech Recent Developments
  49. 6.9 Amoy Diagnostics
  50. 6.9.1 Amoy Diagnostics Company Information
  51. 6.9.2 Amoy Diagnostics Business Overview
  52. 6.9.3 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  54. 6.9.5 Amoy Diagnostics Recent Developments
  55. 6.10 BGI Group
  56. 6.10.1 BGI Group Company Information
  57. 6.10.2 BGI Group Business Overview
  58. 6.10.3 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  60. 6.10.5 BGI Group Recent Developments
7 North America
  1. 7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  2. 7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  3. 7.2.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026)
  4. 7.2.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032)
  5. 7.2.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032)
  6. 7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  7. 7.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026)
  8. 7.3.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032)
  9. 7.3.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032)
  10. 7.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
  11. 7.4.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  13. 7.4.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
  14. 7.4.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  2. 8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  3. 8.2.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032)
  6. 8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  7. 8.3.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032)
  10. 8.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
  11. 8.4.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  2. 9.2 China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  3. 9.2.1 China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026)
  4. 9.2.2 China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032)
  5. 9.2.3 China Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032)
  6. 9.3 China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  7. 9.3.1 China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026)
  8. 9.3.2 China Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032)
  9. 9.3.3 China Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  2. 10.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  3. 10.2.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032)
  6. 10.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  7. 10.3.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032)
  10. 10.4 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
  11. 10.4.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst